22nd Century Group (Nasdaq: XXII) Strengthens Balance Sheet to Accelerate the Expansion of VLN Launch
July 21, 2022 10:00 ET
|
22nd Century Group, Inc
Announces $35 Million Above Market FinancingBolsters Company’s Position with Ongoing Strategic Discussions BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII),...
22nd Century Announces $35 Million Registered Direct Offering Priced Above Market under Nasdaq Rules
July 21, 2022 09:00 ET
|
22nd Century Group, Inc
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), leading agricultural biotechnology company dedicated to improving human health with reduced nicotine...
22nd Century Group (Nasdaq: XXII) Supports Federal Proposal to Require Less Nicotine in All U.S. Cigarettes
June 22, 2022 09:25 ET
|
22nd Century Group, Inc
FDA’s Proposed Rule Draws on Research That Supports Reduced Nicotine Content Cigarettes Are Less Addictive22nd Century Group’s FDA MRTP Authorized 95% Reduced Nicotine Cigarette Products Is Already...
22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO
June 16, 2022 08:30 ET
|
22nd Century Group, Inc
CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group,...
22nd Century Group (Nasdaq: XXII) to Participate in LD Micro, Roth Capital Investor Meetings
May 27, 2022 09:25 ET
|
22nd Century Group, Inc
BUFFALO, N.Y., May 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine...
22nd Century Group (Nasdaq: XXII) Announces John J. Miller Joins Its Tobacco Business
May 23, 2022 09:25 ET
|
22nd Century Group, Inc
Highly Regarded for His Extensive Sales and Marketing Experience in the Tobacco Industry Expands and Further Strengthens the Company’s Team of Tobacco Industry Experts BUFFALO, N.Y., May 23, 2022 ...
22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform
May 18, 2022 16:30 ET
|
22nd Century Group, Inc
Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMOConsistent, Reliable, High-Quality Cannabinoids and Cannabinoid Infused Products for...
22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company
May 13, 2022 09:16 ET
|
22nd Century Group, Inc
Provides Transformational Platform to Rapidly Grow Hemp/Cannabis FranchiseTransaction Immediately Accretive and Will Double Company’s Total RevenueAdds Significant Commercial Scale to Existing...
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the First Quarter 2022
May 05, 2022 06:00 ET
|
22nd Century Group, Inc
Launched VLN® Pilot Program in Chicago with Circle K as First Retail Trade PartnerBegan VLN® Shipments to South Korea for First International LaunchFDA’s Proposed Menthol Ban Could Leave VLN® Menthol...
22nd Century Group (Nasdaq: XXII) Expects VLN® Menthol King Reduced Nicotine Cigarettes To Be Exempted From FDA’s Proposed Ban on Menthol Cigarettes
April 29, 2022 09:30 ET
|
22nd Century Group, Inc
Exemption Would Leave 22nd Century’s VLN® Product as the Only Menthol Cigarette on the Market VLN® Menthol King Reduced Nicotine Cigarettes Are Solution To Help Current Menthol Smokers Smoke Less and...